The latest update enables support for more therapies and isotopes and adds a single-time point workflow to ease clinical use.
DOSIsoft, SA, a provider of patient-specific imaging and dosimetry software solutions for radiation oncology and nuclear medicine, announced its latest product release, PLANET Onco Dose version 3.2, which recently received US Food and Drug Administration (FDA) 510(k) clearance.
The novel PLANET platform is designed to incorporate a multi-radionuclide approach, implement multi-workflow solutions, and support multi-therapy applications for both selective internal radiation therapy (SIRT) and molecular radiation therapy (MRT) while ensuring compliance with US standards.
Although a previous version of PLANET Onco Dose was FDA 510(k)-cleared for use with 90Y resin and glass microspheres, this new clearance for the latest software version expands clinical capabilities to include dose computation for Iodine and lutetium. It also offers the flexibility to integrate additional beta- and gamma-emitting isotopes.
Already clinically marketed in the US for oncology features and 90Y-SIRT post-treatment dosimetry, the new version of PLANET Onco Dose enhances MRT dosimetry (177Lu and 131I) workflows. It implements full 3D and 2D/3D hybrid methods for multi-time point workflows, as well as the newly introduced single-time point workflow to reduce workload, enhance patient comfort, and streamline clinical processes.
In this context, the user can benefit from two approaches to perform dosimetry from a single-time point image acquisition: leveraging pharmacokinetics from the prior cycle or applying the population-based/Hänscheid approach.
Expanded to Support a Broad Range of Treatments
The software can perform multiple therapies, including 177Lu-PSMA (prostate-specific membrane antigen) therapy, 177Lu-PRRT (peptide receptor radionuclide therapy), and 90Y radioembolization therapies.
Additionally, PLANET Onco Dose version 3.2 operates on a new, long-term supported operating system with enhanced cybersecurity, ensuring compatibility with the latest workstation generations. Validated against thorough Monte-Carlo simulations, this new release also benefits from GPU acceleration to deliver significantly improved performance.
“PLANET Onco Dose is now available for clinical implementation in the US, supporting multiple therapies, radionuclides, and workflows. This achievement is the result of a collective effort by DOSIsoft to meet all US FDA requirements,” says Jean-Elie Kafrouni, CEO at DOSIsoft Inc, in a release. “This new version positions PLANET Onco Dose ahead of the competition, offering clinicians a comprehensive and adaptable solution for precision dosimetry. We look forward to seeing US patients benefit from this safe and effective device designed for radiopharmaceutical therapy.”
The software also has received MDR CE Mark certification.
Photo caption: PLANET Onco Dose version 3.2
Photo credit: DOSIsoft
